Epigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation, Histone Modification and miRNA Expression)

Repost This

Dallas, TX -- (SBWIRE) -- 10/04/2012 -- This report Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.Mabs” and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenomics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression.

Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.

Epigenomic Mechanisms Discussed in the report include:

- DNA methylation
- Histone Acetylation
- Histone Phosphorylation
- Methylation
- Sumoylation
- Histone “chaperones”
- MicroRNAs (miRNAs)

The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies. In doing so, the report provides:
- Discussion of the Basic Science and Mechanisms Behind Epigenomics
- Activities of Top Companies in the Market
- Interviews with Researchers and Private Sector Leaders
- Market Estimates for Current Epigenomic Drugs and Forecast to 2017
- Market Estimates for Current Epigenomic Diagnostics and Comparison to Next Gen Cancer Diagnostics Market
- Analyst Conclusions Regarding the Future Market for Epigenomics
- Key Healthcare Segments Impacted by Epigenomics
- Examples of Clinically Relevant Epigenetic Biomarkers
- Currently Approved Epigenomic Drugs
- Epigenetic Drivers of Disease
- Pharmaceutical R&D: A Need for Better Returns
- Look at Applications in Alzheimer’s Disease, Mental Illness, Auto-Immune Diseases, Autism and Cardiovascular Disease

The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market. As the report states:
“In the examination of Google hits for “Epigenomics,” the phrases “exciting”, “state of the art”, “cutting edge”, “innovative”, “breakthrough” and other clichés are encountered over and over. These terms are frequently employed to cover up ideas, concepts and scientific discoveries that may NOT be cutting edge or state of the art and may be past their time, or may never have reached their time. For this reason the report will consider which of these technologies have value and may be ripe for exploitation.”

The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.

Buy your copy of this report @ http://www.rnrmarketresearch.com/epigenetics-applications-for-pharmaceuticals-and-diagnostics-methylation-histone-modification-and-mirna-expression-market-report.html .

Companies Active in Epigenomics
1. Enzo Life Sciences
2. Epigenomics AG
3. Epiontis
4. Exact Sciences
5. Illumina
6. Novus Biologicals
7. Oncomethylome Sciences
8. Valirx
9. Volition Singapore
10. Therapeutic Companies
11. Acetylon Pharmaceuticals
12. Acylin Therapeutics
13. CellCentric
14. Celdex
15. Celgene
16. Celzome (UK/DE)
17. Chroma Therapeutics
18. Constellation Pharma
19. Eisai Co. Ltd
20. Epitherapeutics
21. EpiZyme
22. Methyl Gene
23. Novartis:
24. Orion
25. RaNA Therapeutics
26. Syndax Pharmaceuticals Inc.
27. ValiRX (UK)
28. Epigenetics research products supply companies
29. Active Motif
30. Diagenode
31. Epigentek
32. Life Technologies
33. Qiagen
34. Sigma-Aldrich
35. Zymo Research Products

Table Of Exhibits

Table 1-1:The most common epigenetic alterations
Figure 2-1 Timeline of epigenetic discoveries ourtesy Constellation Pharma
Table 2-1 The most common epigenetic alterations
Figure 2-2 Agouti Mice
Figure 2-3 Classic DNA methylation reaction
Figure 2-4 The molecule 5-hydroxymethylcytosine
Figure 2-5 DNA molecule wrapped twice around a Hisotne Octamer to make a Nucleosome
Table 2-2 Varieties of histone modification and their properties
Figure 2-6 Acetylation and deacetylation of lysene residues
Figure 2-7 Shilatifard A. 2008
Table 3-1: Examples of Clinically Relevant Epigenetic Biomarkers
Table 4-1: Currently FDA-approved Epigenetic-Based Drugs
Figure 4-1: Structures of (A) 5-aza 2'-deoxycytidine (5 aza - dC, decitabine) and (B) zebularine
Figure 4-2: U.S. FDA-approved Epigenetic-Acting Drugs
Table 4-3: Prevalance of Autism as a Function Time, 200-2008
Table 4-4: Current Autism Therapies
Figure 4-3: Map of the 11p15 imprinted region
Table 5-1: Some Important Epigenetics Diagnostics Companies
Table 5-2: The Epigenetics Land Grab: R&D from Major Pharma Companies
Figure 5-2: JUN/EPIZYME An Example of one of Epizyme's inhibitors interacting with an epigenetic enzyme
Figure 5-3: Structure of LBH589 (panobinostat)
Figure 5-4: Action of Panbinostat
Figure 5-5: Structure of Entinostat
Table 6.1:GNP Growth by Country, Region
Table 6.2: Conflicting Worldwide Economic Drivers And Their Impact On Epigenomics Technologies
Figure 6.1: Vast Expenditures, Poor Returns
Table 6.3: Guidelines For A New Stage Of Drug Development
Table 6.4: Epigenomics Therapeutics Market, 2011 and 2017 (millions)
Table 6.5: Global Pharma Market, 2010 and 2015 (billions)
Figure 6.2: Epigenomic Drug Market, 2011 and 2017
Table 6.6: FDA-Approved Epigenetic Anti-Cancer Agents
Figure 6.3: Epigenomics Diagnostics Market, 2010 and 2015
Table 6.7: Next Gen Cancer Diagnostics Market, 2010-2015
Table 6.8: Epigenomics in Cancer Diagnostics, 2010-2015
Table 6.9: Total IVD Market 2007-2011
Table 6.10: Some Current Epigenomics Research Goals
Table 6.11: Cancer Diagnostics Market
Table 6.12: Some Major Companies And Their Activities
Figure 6.4: Publications on Epigenomics and Cardiovascular Disease
Table 6.13: Takeda regional Portfolio Blance As a Bellweather

Contact sales@rnrmarketresearch.com for further information.